Momenta Pharmaceuticals Appoints Jose-Carlos Gutierrez-Ramos, Ph.D. to Board of Directors

CAMBRIDGE, Mass., March 09, 2016 (GLOBE NEWSWIRE) -- Momenta Pharmaceuticals, Inc. (Nasdaq:MNTA), a biotechnology company specializing in the characterization and engineering of complex drugs, today announced the appointment of Jose-Carlos (JC) Gutiérrez-Ramos, Ph.D. to its Board of Directors effective March 9, 2016. Dr. Gutiérrez-Ramos currently serves as Chief Executive Officer and President of Synlogic Inc. and was previously Group Senior Vice President and Global Head of BioTherapeutics Research and Development at Pfizer.

“JC is a very welcome addition to our Board and brings more than twenty years of valuable drug research and development experience from leading global biopharmaceutical companies,” said Craig Wheeler, President and CEO, Momenta Pharmaceuticals. “JC’s deep scientific knowledge in immunology and oncology and broad expertise in biologics production and clinical drug development will be invaluable to the Company as we advance our biosimilar and novel drug candidates through development and toward commercialization.”

Dr. Gutiérrez-Ramos has served as Chief Executive Officer and President of Synlogic Inc., since May 2015. Previously, he served as Group Senior Vice President and global head of the BioTherapeutics Research at Pfizer where he was responsible for more than 25 novel programs across the full spectrum of clinical development, re-launched efforts in Rare Disease Discovery and Development and founded the Centers for Therapeutic Innovation. He also oversaw and enhanced the biologics platform for the company from early discovery to entry in manufacturing. Dr. Gutiérrez-Ramos was previously Senior Vice President and Head of the Immuno-inflammation Center for Drug Discovery (iiCEDD) at GSK, where he founded entrepreneurial units such as Epinova and Tempero focused in translating novel areas of science (Epigenetics, Tregs, etc) into therapeutics. Prior to his work in the pharmaceutical industry, Dr. Gutiérrez-Ramos held senior leadership positions at several biotech companies, including Senior Vice President and Head of R&D at Avidia Inc. and Peptimmune Inc. He began his career in the drug industry at Millennium Pharmaceuticals serving as Vice President of Inflammation Drug Discovery. Dr. Gutiérrez-Ramos holds a Ph.D. in immunochemistry from the Autonoma University in Madrid, Spain.

About Momenta

Momenta Pharmaceuticals is a biotechnology company specializing in the detailed structural analysis of complex drugs and is headquartered in Cambridge, MA. Momenta is applying its technology to the development of generic versions of complex drugs, biosimilar and potentially interchangeable biologics, and to the discovery and development of novel therapeutics for oncology and autoimmune indications.

To receive additional information about Momenta, please visit the website at, which does not form a part of this press release.

Our logo, trademarks, and service marks are the property of Momenta Pharmaceuticals, Inc. All other trade names, trademarks, or service marks are property of their respective owners.

Forward Looking Statements

Statements in this press release regarding management's future expectations, beliefs, intentions, goals, strategies, plans or prospects, are forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including but not limited to statements about Dr. Gemayel benefitting the Company; advancing our product pipeline; and bringing multiple products to market in the coming years. Forward-looking statements may be identified by words such as "anticipate," "believe," "continue," "could," "hope," "target," "project," "goal," "objective," "guidance," "plan," "potential," "predict," "might," "estimate," "expect," "intend," "may," "seek", "should," "will," "would," "look forward" and other similar words or expressions, or the negative of these words or similar words or expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors, including those referred to under the section "Risk Factors" in the Company's Annual Report on Form 10-K for the year ended December 31, 2015, filed with the Securities and Exchange Commission, as well as other documents that may be filed by the Company from time to time with the Securities and Exchange Commission. As a result of such risks, uncertainties and factors, the Company's actual results may differ materially from any future results, performance or achievements discussed in or implied by the forward-looking statements contained herein. The Company is providing the information in this press release as of this date and assumes no obligations to update the information included in this press release or revise any forward-looking statements, whether as a result of new information, future events or otherwise.

INVESTOR CONTACT: Sarah Carmody Momenta Pharmaceuticals 1-617-395-5189 MEDIA CONTACT: Karen Sharma MacDougall Biomedical Communications 1-781-235-3060

Source:Momenta Pharmaceuticals, Inc.